Introduction
▼ Blood pressure and vascular functions are regulated by numerous circulating and local factors. The main regulatory system is renin-angiotensin system (RAS) ( • ▶ Fig. 1 ), but also other endothelial enzymes produce highly active compounds such as prostacyclin and nitric oxide. The most biologically active substance in RAS is angiotensin II (Ang II), which is broken down from angiotensin I (Ang I) mainly by angiotensin converting enzyme I (ACE-1) but also by chymase and cathepsin G. ACE-1 also degrades bradykinin, a vasodilatory peptide into inactive fragments ( • ▶ Fig. 1 ). RAS contains a number of other enzymes besides ACE-1 which have an important role in blood pressure regulation. Some of these enzymes have a direct eff ect on Ang II but they also participate in the conversion of substances such as angiotensin-(1-7) (Ang-(1-7)) with potent vasodilatory and cardioprotective eff ects. [ 1 -3 ] In addition to classical AT-1 receptors, new focus has also been set to vasodilatory AT-type 2 and Ang-(1-7)-Mas- In the fermentation of milk by certain lactic acid bacteria, casein is degraded into bioactive tripeptides shown to lower blood pressure in experimental animal models and in mildly hypertensive humans. This eff ect is suggested to result mainly in inhibition of angiotensin converting enzyme 1 (ACE-1). Due to the complexity of renin-angiotensin system (RAS), several other enzymes than ACE-1 can participate in the production of vasoactive components. Therefore, in the present study we investigated eff ects of tripeptides isoleucine-proline-proline (IPP), valine-proline-proline (VPP) and leucine-proline-proline (LPP) on some endothelial enzymes that are important in RAS or oth-erwise have a role in the endothelial function. The enzymes investigated were renin, chymase, neutral endopeptidase (NEP), prolyl oligopeptidase (POP), cathepsin G, endothelin converting enzyme 1 (ECE-1), and cyclooxygenase 1 and 2 (COX -1 and COX-2). The tripeptides inhibited prolyl oligopeptidase (POP) dose-dependently. IPP was the most potent inhibitor (IC 50 486 ± 95 μM). Contrary, cathepsin G was activated by IPP, VPP and LPP as well as the amino acids proline and isoleucine. The other investigated enzymes were not aff ected. Inhibition of POP and activation of cathepsin G do not explain the blood pressure lowering eff ects of the tripeptides. Thus the inhibition of ACE-1 remains the most plausible mechanism of the antihypertensive eff ects of the tripeptides. 
Materials and methods

▼
Renin assay
Renin (Human recombinant) activity was measured using a commercial fl uorometric kit (SensoLyte ® 520 Renin Assay Kit, AnaSpec, San Jose, CA, USA). The activity of renin was determined using 5-FAM/QXL™520 fl uorescence resonance energy transfer (FRET) peptide as a substrate which renin degrades into 2 separate fragments. The fl uorescent can be monitored at ex/ em = 490/520 nm (Perkin Elmer Life Science, WALLAC VICTOR 2 1420, Turku; Finland). Incubation time was 60 min at 37 °C including 11 fl uorescent measurements with all the tripeptides concentrations (1 μM-3.3 mM). The tripeptides were solved and diluted in the assay buff er.
Chymase assay
Chymase (Human recombinant) activity was measured using commercial kit (Chymase activity kit, Sigma-Aldrich, Jerusalem, Israel). The method is based on the ability of chymase to degrade N-Succinyl-Ala-Ala-Pro-Phe-p -nitroanilide into a colorimetric product which can be monitored at wavelength 405 nm (Multiscan RC, Labsystems, Helsinki, Finland). Incubation time was 50 min at 37 °C including 9 measurements with all tripeptides concentrations (1 μM-1 mM). The tripeptides were solved and diluted in the assay buff er.
Neutral endopeptidase (NEP) assay
NEP activity was measured using the method by Florentin et al. [ 14 ] with small modifi cations. Assay substrate was DAGNPG which was diluted fi rst in methanol and thereafter in assay buff er Tris-HCl (50 mM, pH 7.4), the fi nal concentration of the substrate in the reaction was 50 μM. Methanol concentration in the reaction was 0.2 %. The method was based on NEPs ability to degrade DAGNPG of which fl uorescense was monitored at ex/ em = 342/580 nm (Perkin Elmer Life Science, WALLAC VICTOR 2 1420). Incubation time was 120 min at 37 °C including 7 measurements with all tripeptides concentrations (1 μM-1 mM). The tripeptides and the enzyme were solved and diluted in the assay buff er.
Prolyl oligopeptidase (POP) assay
POP activity was measured using the method design by Stanziola et al. [ 15 ] and Atack et al. [ 16 ] . Assay substrate was Z-Gly-Pro-AMC from which POP can cleave AMC group, a fl uorescent substance which can be measured in ex/em = 355/460 nm (Perkin Elmer Life Science, WALLAC VICTOR 2 1420). The assay buff er was Tris (25 mM)-NaCl (250 mM)-dithiotreitol (DTT, 2.5 mM) buff er (pH 7.5). The enzyme, the tripeptides and the substrate were diluted in the assay buff er. The fi nal concentrations of the enzyme, the substrate and the tripeptides in reaction were 0.005 μg, 50 μM and 1 μM-3.3 mM, respectively, and the incubation time was 60 min, including 10 measurements at room temperature.
Cathepsin G assay
Cathepsin G activity was measured using the method by Barret [ 17 ] with a small modifi cations. The method is based on the ability of cathepsin G to degrade the substrate N-Suc-Ala-Ala-Pro-Phe-pNA into a colorimetric product that can be measured spectrophotometrically at 410 nm (Multiscan RC, Labsystems, Helsinki, Finland). The substrate was diluted in dimethyl sulfoxide (DMSO). The fi nal concentration of the substrate and DMSO in the reaction was 200 μM and 25 %, respectively. The enzyme (0.1-0.2 mU/reaction) was diluted in ice cold distilled water. The tripeptides were solved and diluted in HEPES-NaOH buff er (100 mM, pH 7.5) which was the assay buff er. The incubation time was 70 min at 37 °C including 11 measurements with all tripeptide concentrations (0.1 μM-3.3 mM).
Endothelin converting enzyme I (ECE-1) assay
ECE-1 activity was measured using Activity Assay Protocol by R&D systems. The assay procedure is based on the ability of ECE-1 to degrade MCA-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys-(DNP)OH and the development of the fl uorescence products can be measured in ex/em = 320/405 nm (Perkin Elmer Life Science, WALLAC VICTOR 2 1420). The assay buff er was 0.1 mM 2-(N-morpholino)ethanesulfonic acid (MES) -0.1 mM NaCl -buff er (pH 6). The substrate (10 μM), the enzyme (0.005 μg) and the tripeptides (1 μM-3.3 mM) were solved and diluted in the assay buff er. The incubation time was 60 min at room temperature including 10 measurements with all tripeptide concentrations. 
Cyclooxygenase 1 (COX-1) and cyclooxygenase (COX-2) assayes
The activities of COX-1 and COX-2 were measured using commercial fl uorescence-based assay (COX Fluorescent Inhibitor Screening Assay Kit, Cayman Chemical Company, Ann Arbor, MI, USA). The method includes 2 reactions: COX-1 and COX-2 form prostaglandin G 2 (PGG 2 ) from arachidonic acid in the fi rst reaction and in the second reaction PGG 2 reacts with 10-acetyl-3.7dihydroxyphenoxazine (ADPH) forming fl uorescent product resorufi n which can be measured at ex/em = 530/590 nm. The tripeptides (1 μM-3.3 mM) were solved and diluted in the assay buff er. The incubation time was 60 min at room temperature including 10 measurements with all tripeptide concentrations.
Statistical analysis
The results are presented as mean ± SEM. Statistical analyses were performed using GraphPad Prism software (version 4.02). One way analysis of variances (ANOVA) followed by Dunnett's multiple comparison tests were used to compare area under a curve (AUC) results. AUC was calculated from the dose-response curves. The activities of the enzymes in diff erent groups were presented as percentage from the control (group without the tripeptide) activity. Diff erence was considered signifi cant if p-value < 0.05.
Results
▼
IPP, VPP and LPP inhibited POP dose-dependently at high micromolar concentrations ( • ▶ Fig. 2 ). IC 50 -values for IPP, VPP and LPP were 486 ± 95, 761 ± 146 and 875 ± 192 μM (mean ± SEM), respectively. The amino acids proline and isoleucine showed no inhibitory eff ects on POP (data not shown). Interestingly, all the investigated tripeptides increased the activity of cathepsin G ( • ▶ Fig. 3 ). Also amino acids proline, isoleucine and arginine elevated cathepsin G activity ( • ▶ Fig. 4 ). Activation was up to 50 % over the control values with all the investigated tripeptides and amino acids. Proline activated cathepsin G at lower concentrations (0.1-10 μM) than IPP, VPP and LPP and amino acids arginine (all 1 μM-3.3 mM) and isoleucine (1-100 μM). The tripeptides IPP and VPP showed no inhibition or activation of the other investigated enzymes renin, chymase, NEP, ECE-1, COX-1 and COX-2 (n = 3-11) at the concentrations between 1 μM-3.3 mM (Data not shown). 
Discussion
▼
In the present study, we investigated the eff ects of milk casein derived tripeptides (IPP, VPP and LPP) on other blood pressure and vascular function regulating enzymes than ACE-1 in vitro using pure commercial enzymes. ACE-1 was left outside of the analysis because the eff ect of tripeptides on ACE-1 has been already tested by us and others. [ 6 , 13 ] , Viitala R. et.al unpublished data The tested enzymes were renin, chymase, neutral endopeptidase (NEP), cathepsin G and prolyl oligopeptidase (POP) from RAS and vascular enzymes cyclooxygenase 1 and 2 (COX-1 and COX-2) and endothelin converting enzyme 1 (ECE-1). Renin originating from kidney cleaves angiotensinogen to Ang I which is further converted to Ang II by ACE-1. This can also be carried out by chymase and cathepsin G. Cathepsin G is also able to split Ang II directly from angiotensinogen. POP forms Ang-(1-7) from Ang I and Ang II and NEP from Ang I. Also angiotensin converting enzyme 2 (ACE-2) can create Ang-(1-7). ACE-1, NEP and POP participate in the degradation of bradykinin into inactive fragments ( • ▶ Fig. 1 ) [ 1 , 2 , 18 , 19 ].
In the present study, IPP, VPP and LPP inhibited POP dosedependently. This, however, does not explain their blood pressure lowering eff ects because POP converts a vasodilatory product Ang(1-7) from Ang I and Ang II. Ang(1-7) is able to stimulate recently describe Mas-receptors ( • ▶ Fig. 1 ). Furthermore, relatively high concentrations of the tripeptides were needed for inhibition of POP compared to ACE-1 inhibition [ 6 , 13 ] . IC 50 -values were higher than found in plasma after a single dose to the rat [ 20 ] . However, IPP seems to accumulate in the tissues and thus in vivo give slight pharmacological eff ect.
Bradykinin is also a substrate for POP ( • ▶ Fig. 1 ), in addition to Ang I and Ang II at least in in vitro conditions [ 19 , 22 , 23 ] . It may be possible that Ang-(1-7), produced by POP, balances its bradykinin degradation eff ects in the regulation of blood pressure and vascular function, and therefore POP does not markedly aff ect blood pressure. However, POP-like activity has been shown to be increased during ACE-1 inhibition in rats [ 23 ] . Similarly, also Ang-(1-7) levels are increased during ACE-1 inhibition in rats and in humans [ 24 ] . Incubation of mesenteric arteries with IPP improved Ang-(1-7) -and bradykinin-induced mesenteric artery relaxation [ 5 ] . This may be due to POP/NEP/ACE-2-Ang(1-7)-Mas-reseptor axis and due to ACE-1 inhibition caused by IPP. It is also possible that POP and other Ang-(1-7) forming enzymes, such as NEP and ACE-2, play a physiological role during ACE-1 inhibition or in special pathological situations. Despite numerous studies [ 18 , 19 , 21 , 22 , 24 , 25 ] , the exact physiological role of POP is unclear. POP cleaves short naturally occurring proline containing peptides on the carboxy side of proline residues. For that reason it may have a role in modulating neuronal peptides and hormones containing proline residues such as substance P and arginine vasopressin. It has been identifi ed as a potential target in cognitive function and in some neurodegenerative disease and POP inhibitors have been utilized for drug development mostly for neurological disorders and as memory enhancers [ 24 , 25 ] . Interestingly, the three tripeptides and all investigated amino acids elevated cathepsin G activity. The results disagree with a previous study which measured the eff ects of tripeptides on cathepsin G [ 13 ] . In that study, tripeptides had no eff ect on cathepsin G but the incubation time was only 10 min while in the present study it was 70 min. It may be possible that the cathepsin G activating eff ect was not to seen in the short incubation. This is supported by our own in vitro vascular tests [ 8 ] . In addition, the eff ects of amino acids were not tested in our previous study [ 13 ] . Concerning in vivo condition amino acids isoleucine and proline stimulated cathepsin G already at such low concentrations which could mean physiological relevance of the fi ndings. Activation of cathepsin G cannot explain the decrease of blood pressure and the improvement of vascular function because cathepsin G converts Ang II from angiotensinogen and Ang I ( • ▶ Fig. 1 ). These fi ndings support the assumption that main mechanism for the antihypertensive eff ect and vascular function improvement by the tripeptides is inhibition of ACE-1. Physiological and pathophysiological compounds can activate cathepsin G. Brecher et al. [ 26 ] found that acetaldehyde activated cathepsin G at high millimolar concentrations by ca. 50 % similarly to the peptides and amino acids in the present study. One limitation of the present study is that it was carried out using pure peptides and enzymes in vitro, thus not in physiological conditions. However, these fi ndings show that bioactive, antihypertensive milk-derived peptides are not only ACE-1 inhibitors but have also other eff ects on the components of RAS. Furthermore, the present study indicates the complexity of the RAS with its numerous enzymes of which inhibition or activation can change the balance between vasoconstrictive and vasodilating components to unexpected directions. Ex vivo and in vivo experiments are warranted to clarify possible physiological relevance of the fi ndings
